Claeson G
Thrombosis Research Institute, London, UK.
Blood Coagul Fibrinolysis. 1994 Jun;5(3):411-36.
The synthesis of peptides as imitations of the thrombin cleavage site of fibrinogen has led to sequences with affinity for the enzyme. These peptides were first developed as chromogenic and fluorogenic substrates for thrombin. The same idea was also used to generate peptide substrates for other serine proteases in blood coagulation and fibrinolysis. Amidolytic methods based upon the substrates have revolutionized assays of proenzymes, enzymes, cofactors and inhibitors in research as well as in clinical laboratories. Like peptidomimetics based only on Arg (P1 of the natural substrate) or Arg analogues, these amino acid sequences also have been developed as active site directed inhibitors of thrombin and of factor Xa. A further interesting development is the synthesis of bivalent thrombin inhibitors which, like hirudin, bind to the thrombin active centre as well as to its anionic exosite. Recently, also, it has been shown that the positively charged side chain of P1 Arg is not an absolute necessity for binding a peptide to the active site of thrombin. Several of the new thrombin inhibitors show interesting properties for pharmaceutical development and some of them are on clinical trials.
作为纤维蛋白原凝血酶裂解位点模拟物的肽合成,已产生了对该酶具有亲和力的序列。这些肽最初是作为凝血酶的显色和荧光底物开发的。同样的理念也被用于生成用于血液凝固和纤维蛋白溶解中其他丝氨酸蛋白酶的肽底物。基于这些底物的酰胺水解方法彻底改变了研究以及临床实验室中对酶原、酶、辅因子和抑制剂的检测。与仅基于精氨酸(天然底物的P1)或精氨酸类似物的拟肽一样,这些氨基酸序列也已被开发为凝血酶和Xa因子的活性位点定向抑制剂。一个更有趣的进展是二价凝血酶抑制剂的合成,它与水蛭素一样,既能结合凝血酶活性中心,也能结合其阴离子外位点。最近还表明,P1精氨酸带正电荷的侧链并非肽与凝血酶活性位点结合的绝对必要条件。几种新型凝血酶抑制剂在药物开发方面显示出有趣的特性,其中一些正在进行临床试验。